Fluoroquinolones: Then and now

Compendium: Continuing Education For Veterinarians

Volumn 32, Issue 7, 2010, Pages

  Pallo Zimmerman, Lidia M ^a   Byron, Julie K ^a   Graves, Thomas K ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); CANIS FAMILIARIS;

EID: 77957574886     PISSN: 19408307     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Martinez M, McDermott P, Walker R. Pharmacology of the fuoroquinolones: a perspective for the use in domestic animals. Vet J 2006;1172:10-28.
2. Ball P. Quinolone generations: natural history or natural selection. J Antimicrob Chemother 2000;4(suppl T1): 17-24.
3. Litster A, Moss S, Honnery M, et al. Clinical effcacy and palatability of pradofoxacin 2.5% oral suspension for the treatment of bacterial lower urinary tract infections in cats. J Vet Intern Med 2007;21:990-995.
4. Orbifoxacin. In: Plumb DC. Veterinary Drug Handbook. 6th ed. Ames, Iowa: Blackwell Publishing Professional; 2008:670-671.
5. Gellert M, Mizuuchi K, O'Dea MH, et al. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci 1977;74:4772-4776.
6. Boothe DM. Antibiotic drugs. In: Small Animal Clinical Pharmacology and Therapeutics. Philadelphia: WB Saunders; 2001:162-166.
7. Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fuoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci 1997;94:13991-13996.
8. Zechiedrich EL, Cozzarelli NR. Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli. Genes Dev 1995;9:2859-2869.
9. Boothe DM, Boeckh A, Simpson B, Dubose K. Comparison of pharmacodynamics and pharmacokinetic indices of effcacy for 5 fuoroquinolones toward pathogens of dogs and cats. J Vet Intern Med 2006;20:1297-1306.
10. Albarellos GA, Kreil VE, Landoni M F. Pharmacokinetics of ciprofoxacin after single intravenous and repeat oral administration to cats. J Vet Pharmacol Ther 2004;27:155-162.
11. Dudley MN. Pharmacokinetics and pharmacodynamic properties of new quinolone anti-infectives. Hospital Formul 1987;22:9-15.
12. Carlier MB, Scorneaux B, Zenebergh A, et al. Cellular uptake, localization and activity of fuoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990;26(suppl B): 27-39.
13. Koussa, SL, Hage Chahine SL, Samaha EI, Riachi MA. Generalized status epilepticus possibly induced by gatifoxacin. Eur J Neurol 2006;13:671-672.
14. Hori S, Kizu J, Kawamura M. Effects of anti-infammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-infammatory drugs. J Infect Chemother 2003;9:314-320.
15. Ciprofoxacin. In: Plumb DC. Veterinary Drug Handbook. 6th ed. Ames, Iowa: Blackwell Publishing Professional; 2005:197-198.
16. Difoxacin. In: Plumb DC. Veterinary Drug Handbook. 6th ed. Ames, Iowa: Blackwell Publishing Professional; 2008:289-290.
17. Enrofoxacin. In: Plumb DC. Veterinary Drug Handbook. 6th ed. Ames, Iowa: Blackwell Publishing Professional; 2008:342-344.
18. Marbofoxacin. In: Plumb DC. Veterinary Drug Handbook. 6th ed. Ames, Iowa: Blackwell Publishing Professional; 2008:557-558.
19. Yabe K, Satoh Y, Ishii T, et al. Early pathophysiologic feature of arthropathy in juvenile dogs induced by ofoxacin, a quinolone antimicrobial agent. Vet Pathol 2004;41:673-681.
20. Egerbacher M, Edinger J, Tschulenk W. Effects of enrofoxacin and ciprofoxacin hydrochloride on canine and equine chondrocytes in culture. Am J Vet Res 2001;62(5):704-708.
21. Burkhardt JE, Hill MA, Carlton WW, Kestarson JW. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difoxacin, a fuoroquinolone. Vet Pathol 1990;27(3):162-170.
22. Takizawa T, Hashimoto K, Minami T, et al. The comparative arthropathy of fuoroquinolones in dogs. Hum Exp Toxicol 1999;18(6):392-399.
23. Ford MM, Dubielzig RR, Giulano EA, et al. Ocular and systemic manifestations after oral administration of a high dose of enrofoxacin in cats. Am J Vet Res 2007;68:190-202.
24. Gelatt KN, van der Woerdt A, Ketring KL, et al. Enrofoxacin associated retinal degeneration in cats. Vet Ophthalmol 2001;4(2):99-106.
25. Wiebe V, Hamilton P. Fluoroquinolone-induced retinal degeneration in cats. JAVMA 2002;221(11):1568-1571.
26. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem 2003;3(3):249-282.
27. Wetzstein HG. Comparative mutant prevention concentrations of pradofoxacin and other veterinary fuoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob Agents Chemother 2005;49(10):4166-4173.
28. Tran JH, Jacoby GA. Mechanism of plasmid mediated quinolone resistance. Proc Natl Acad Sci 2002;99(8):5638-5642.
29. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fuoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999;43(7):1756-1758.
30. Mueller RS, Stephan B. Pradofoxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial. Vet Dermatol 2007;18(3):144-151.
31. Minarini LAR, Darini ALC. First report of plasmid-mediated resistance to quinolones and cefotaxime in an Enterobacter cloacae strain isolated from an outpatient in Brazil. Antimicrob Agents Chemother 2007;51(1):401-402.
32. Sidjabat HE, Townsend KM, Hanson ND, et al. Identifcation of blacmy-7 and associated plasmid-mediated resistance genes in multidrug-resistant Escherichia coli isolated from dogs at a veterinary teaching hospital in Australia. J Antimicrob Chemother 2006;57(5):840-848.
33. US Food and Drug Administration Center for Veterinary Medicine. Human health impact of fuoroquinolone resistant Campylobacter attributed to the consumption of chicken. Accessed June 2010 at www.fda.gov/downloads/ AnimalVeterinary/Safety Health/RecallsWithdrawals/UCM152308.pdf.
34. US Food and Drug Administration Center for Veterinary Medicine. Approval withdrawn for Abbott Laboratories' poultry fuoroquinolone drugs. Accessed June 2007 at www.fda.gov.
35. Cohn LA, Gary AT, Fales WH, Madsen RW. Trends in fuoroquinolone resistance of bacteria isolated from canine urinary tracts. J Vet Diagn Invest 2003;15(4):338-343.
36. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in outpatient urinary isolates: fnal results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2005;26(5):380-388.
37. Farrell DJ, DeRubeis D, Robbins M, Felmingham D. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect 2003;46(2):94-100.
38. Marimon JM, Gomariz M, Zigorraga C, et al. Increasing prevalence of quinolone resistance in human nontyphoid Salmonella enterica isolates obtained in Spain from 1981 to 2003. Antimicrob Agents Chemother 2004;48(10):3789-3793.
39. Arslan H, Azap OK, Ergonal O, Timurkaynak F. Risk factors for ciprofoxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005;56(5):914-918.
40. Abadia AR, Aramayona JJ, Munoz MJ, et al. Ciprofoxacin pharmacokinetics in dogs following oral administration. Zentralbl Veterinarmed A 1995;42(8):505-511.
41. Walker RD, Stein GE, Hauptmann JG, et al. Serum and tissue cage fuid concentrations of ciprofoxacin after oral administration of the drug to healthy dogs. Am J Vet Res 1990;51(6):896-900.
42. Fort Dodge Animal Health. Dicural drug label information. Accessed June 2010 at www.vin.com.
43. Bayer Healthcare LLC. Baytril drug label information. Accessed June 2010 at www.vin.com.
44. Hostutler RA, Luria BJ, Johnson SE, et al. Antibiotic-responsive histiocytic ulcerative colitis in 9 dogs. J Vet Intern Med 2004;18(4):499-504.
45. Davies DR, O'Hara AJ, Irwin PJ, Guilford WG. Successful management of histiocytic ulcerative colitis with enrofoxacin in two boxer dogs. Aust Vet J 2004;82(1-2): 58-61.
46. Pfzer Animal Health. Zeniquin drug label information. Accessed June 2010 at www.vin.com.
47. Schering-Plough Animal Health Corporation. Orbax drug label information. Accessed June 2010 at www.vin.com.
48. Bayer Animal Health. Mutant prevention concentration of pradofoxacin against Porphyromonas gingivalis. Vet Microbiol 2007;121(1-2): 194-195.